ValuEngine upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a strong-buy rating in a research report report published on Saturday.

Several other equities analysts have also issued reports on the company. Stifel Nicolaus set a $31.00 target price on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 8th. Jefferies Financial Group assumed coverage on Vanda Pharmaceuticals in a research note on Thursday, November 8th. They issued a buy rating and a $26.00 target price on the stock. Oppenheimer set a $29.00 target price on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 8th. Zacks Investment Research lowered Vanda Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, November 7th. Finally, BidaskClub lowered Vanda Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, November 1st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $27.43.

VNDA opened at $22.57 on Friday. Vanda Pharmaceuticals has a 1 year low of $12.70 and a 1 year high of $25.07. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -64.49 and a beta of 1.06.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The company had revenue of $49.13 million for the quarter, compared to analyst estimates of $49.44 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. The firm’s quarterly revenue was up 18.9% compared to the same quarter last year.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in shares of Vanda Pharmaceuticals by 2.5% during the second quarter. Renaissance Technologies LLC now owns 1,681,250 shares of the biopharmaceutical company’s stock worth $32,028,000 after acquiring an additional 41,200 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth about $240,000. BlackRock Inc. grew its stake in shares of Vanda Pharmaceuticals by 16.3% during the second quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after acquiring an additional 693,922 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $754,000. Finally, Macquarie Group Ltd. boosted its position in Vanda Pharmaceuticals by 12.1% in the second quarter. Macquarie Group Ltd. now owns 2,555,004 shares of the biopharmaceutical company’s stock valued at $48,673,000 after buying an additional 276,057 shares during the last quarter. Institutional investors and hedge funds own 95.54% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Stock Symbols and CUSIP Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.